Avalon GloboCare shares are trading lower. The company announced its Laboratory Services MSO launched a direct-to-consumer and non-invasive DNA test in the U.S. that tests for potential predisposition to opioid dependence.
Portfolio Pulse from Benzinga Newsdesk
Avalon GloboCare shares are trading lower after the company announced its Laboratory Services MSO launched a direct-to-consumer and non-invasive DNA test in the U.S. that tests for potential predisposition to opioid dependence.
July 31, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Avalon GloboCare shares are trading lower following the launch of a new direct-to-consumer DNA test for opioid dependence predisposition.
The launch of the new product has not been well-received by the market, leading to a decline in Avalon GloboCare's share price. Investors may be concerned about the market potential or the costs associated with the new product.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100